Celltrion Crescita futura

Future criteri di controllo 5/6

Celltrion prevede che gli utili e i ricavi cresceranno rispettivamente di 73.6% e 25.4% all'anno. Si prevede che l'EPS crescerà di 73.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 8.4% in 3 anni.

Informazioni chiave

73.6%

Tasso di crescita degli utili

73.8%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	72.9%
Tasso di crescita dei ricavi	25.4%
Rendimento futuro del capitale proprio	8.4%
Copertura analitica	Good
Ultimo aggiornamento	20 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Nov 22

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Mar 15

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Feb 24

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Feb 03

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 13

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Dec 23

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Dec 02

Previsioni di crescita degli utili e dei ricavi

KOSE:A068270 - Stime future degli analisti e dati finanziari passati (KRW Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	5,291,783	1,634,795	1,346,036	1,592,613	19
12/31/2025	4,383,126	1,203,431	1,163,190	1,270,444	20
12/31/2024	3,494,048	463,133	928,100	752,347	18
9/30/2024	2,876,253	187,097	418,332	745,531	N/A
6/30/2024	2,666,611	323,331	83,312	432,328	N/A
3/31/2024	2,315,848	392,826	66,750	422,925	N/A
12/31/2023	2,176,432	535,648	186,106	537,159	N/A
9/30/2023	2,304,473	603,795	129,730	474,877	N/A
6/30/2023	2,277,818	542,616	318,558	660,719	N/A
3/31/2023	2,350,070	582,780	-184,477	138,081	N/A
12/31/2022	2,283,967	526,616	-311,112	864	N/A
9/30/2022	2,376,733	566,168	-23,144	281,444	N/A
6/30/2022	2,133,015	543,369	29,404	350,378	N/A
3/31/2022	1,967,894	482,930	487,131	812,712	N/A
12/31/2021	1,893,401	569,488	617,416	911,159	N/A
9/30/2021	1,788,695	564,777	144,340	719,861	N/A
6/30/2021	1,935,547	597,615	-5,693	535,749	N/A
3/31/2021	1,933,237	608,477	-104,526	405,793	N/A
12/31/2020	1,849,116	517,760	-189,146	350,747	N/A
9/30/2020	1,733,144	512,182	24,017	306,641	N/A
6/30/2020	1,473,428	402,929	129,472	415,876	N/A
3/31/2020	1,279,603	342,041	96,723	395,972	N/A
12/31/2019	1,128,460	301,030	188,226	473,994	N/A
9/30/2019	988,284	230,443	209,922	457,900	N/A
6/30/2019	930,333	225,180	166,169	382,131	N/A
3/31/2019	958,797	228,480	187,319	393,968	N/A
12/31/2018	982,075	245,755	176,969	364,786	N/A
9/30/2018	1,013,790	308,254	261,862	413,841	N/A
6/30/2018	1,014,774	355,009	N/A	408,309	N/A
3/31/2018	997,483	381,655	N/A	413,036	N/A
12/31/2017	949,080	368,222	N/A	485,981	N/A
9/30/2017	883,631	308,461	N/A	460,296	N/A
6/30/2017	819,814	263,666	N/A	494,123	N/A
3/31/2017	758,701	215,812	N/A	366,287	N/A
12/31/2016	670,581	158,958	N/A	230,113	N/A
9/30/2016	630,045	176,699	N/A	145,536	N/A
6/30/2016	631,225	181,015	N/A	74,918	N/A
3/31/2016	614,243	179,605	N/A	113,851	N/A
12/31/2015	603,413	154,090	N/A	77,567	N/A
9/30/2015	534,991	117,389	N/A	45,022	N/A
6/30/2015	470,682	70,144	N/A	156,964	N/A
3/31/2015	481,797	84,083	N/A	170,776	N/A
12/31/2014	471,046	112,676	N/A	145,159	N/A
9/30/2014	373,936	97,604	N/A	184,395	N/A
6/30/2014	349,650	118,987	N/A	164,819	N/A
3/31/2014	232,292	83,007	N/A	95,576	N/A
12/31/2013	226,208	102,455	N/A	137,081	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di A068270 ( 73.6% all'anno) è superiore al tasso di risparmio ( 2.7% ).

Guadagni vs Mercato: Si prevede che gli utili di A068270 ( 73.6% all'anno) cresceranno più rapidamente del mercato KR ( 28.4% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di A068270 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di A068270 ( 25.4% all'anno) crescerà più rapidamente del mercato KR ( 9.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di A068270 ( 25.4% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di A068270 sarà basso tra 3 anni ( 8.4 %).

Celltrion Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 16%

Consensus EPS estimates fall by 21%

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 16%

Consensus EPS estimates fall by 19%

Consensus forecasts updated

Recent updates

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Celltrion Presents Additional Data from Phase III Randomized Controlled Trials to Further Support Biosimilarity for CT-41 (Biosimilar Candidate of Denosumab) and CT-P47 (Biosimilar Candidate of Tocilizumab) At American College of Rheumatology Convergence 2024

Consensus EPS estimates fall by 16%

Celltrion, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Celltrion Presents 2-Year Post-Hoc Analysis Findings for Subcutaneous Infliximab (CT-P13 SC), Highlighting Dose Escalation as an Option for Managing Loss of Response in Inflammatory Bowel Disease

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

European Commission Approves Celltrion's SteQeyma (CT-P43) A Biosimilar to Stelara (ustekinumab), for the Treatment of Multiple Chronic Inflammatory Diseases

Consensus EPS estimates fall by 21%

Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

Celltrion Showcases Promising Results in Phase III study for CT-P47, A Biosimilar Candidate of Roactemra® (Tocilizumab) in Patients with Rheumatoid Arthritis (RA) at EULAR 2024

Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe

Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

First quarter 2024 earnings released: EPS: ₩108 (vs ₩1,156 in 1Q 2023)

Now 21% overvalued after recent price rise

Celltrion, Inc. (KRX:068270) Not Flying Under The Radar

Consensus EPS estimates fall by 14%

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Full year 2023 earnings released: EPS: ₩3,759 (vs ₩3,664 in FY 2022)

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Consensus EPS estimates fall by 16%

Celltrion, Inc., Annual General Meeting, Mar 26, 2024

Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease (IBD)

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 22%

Upcoming dividend of ₩500 per share at 0.3% yield

Consensus EPS estimates fall by 19%

Celltrion, Inc. to Report Nine Months, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

First quarter 2023 earnings released: EPS: ₩1,156 (vs ₩756 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Celltrion Healthcare Announces Canadian Approval of Vegzelma® (Bevacizumab for Injection) for the Treatment of Five Types of Cancer

Upcoming dividend of ₩375 per share

Now 20% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: ₩1,328 (vs ₩907 in 2Q 2021)

Price target increased to ₩210,861

Consensus forecasts updated

Investor sentiment improved over the past week

Price target decreased to ₩194,520

Less than half of directors are independent

Now 20% undervalued after recent price drop

Price target decreased to ₩218,897

Full year 2021 earnings: EPS misses analyst expectations

Consensus revenue estimates increase by 10%

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

Price target decreased to ₩277,071

Third quarter 2021 earnings released: EPS ₩992 (vs ₩1,251 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ₩919 (vs ₩1,013 in 2Q 2020)

Consensus EPS estimates fall to ₩4,214

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

Celltrion, Inc. Receives FDA Emergency Use Authorization for Point of Care Antigen Rapid Test Kit – DiaTrust COVID-19 Ag Rapid Test

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

New 90-day low: ₩300,500

Celltrion, Inc., Annual General Meeting, Mar 26, 2021

Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform

Celltrion’s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Authorisation

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Celltrion Group Announces Positive Top-Line Efficacy and Safety Data from Global Phase II/III Clinical Trial of COVID-19 Treatment Candidate CT-P59

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?